Stockreport

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

Cellectar Biosciences, Inc.  (CLRB) 
Last cellectar biosciences, inc. earnings: 11/12 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.cellectar.com
PDF FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discov [Read more]